Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 5/20 | 0.45 |
| ▸ | CA2 | P00918 | 5/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | KDM5C | P41229 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.39 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4388456 | 0.92 | MEN1 (0.46) | MEN1GAAKMT2ATDP1EPHX1 | |
| SCHEMBL16061043 | 0.91 | MEN1 (0.53) | MEN1GAAKMT2ATDP1EPHX1 | |
| SCHEMBL5041833 | 0.91 | MEN1 (0.51) | MEN1GAAKMT2ATDP1EPHX1 | |
| SCHEMBL1509861 | 0.91 | MEN1 (0.45) | MEN1GAAKMT2ATDP1EPHX1 | |
| SCHEMBL23034976 | 0.91 | MEN1 (0.45) | MEN1GAAKMT2ATDP1EPHX1 | |
| SCHEMBL28348827 | 0.90 | TDP1 (0.54) | MEN1GAAKMT2ATDP1EPHX1 | |
| Succinic Acid SCHEMBL29429364 | 0.89 | GAA (0.56) | MEN1GAAKMT2ATDP1EPHX1 | |
| SCHEMBL1509845 | 0.88 | MEN1 (0.50) | MEN1GAAKMT2ATDP1EPHX1 | |
| SCHEMBL1509910 | 0.88 | MEN1 (0.50) | MEN1GAAKMT2ATDP1EPHX1 | |
| SCHEMBL156911 | 0.86 | GAA (0.58) | MEN1GAAKMT2ATDP1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213735-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2025-07-03 | — | — | US | disclosed |
| CN-114901315-B | Fibroblast Activation Protein (FAP) -targeted imaging and treatment of cancer and other fibrotic and inflammatory diseases | 普渡研究基金会 | 2025-04-29 | — | — | CN | disclosed |
| US-20220409747-A1 | FIBROBLAST ACTIVATION PROTEIN (FAP)-TARGETED IMAGING AND THERAPY OF CANCERS AND OTHER FIBROTIC AND INFLAMMATORY DISEASES | PURDUE RESEARCH FOUNDATION | 2022-12-29 | — | — | US | disclosed |
| US-20220409747-A1 | FIBROBLAST ACTIVATION PROTEIN (FAP)-TARGETED IMAGING AND THERAPY OF CANCERS AND OTHER FIBROTIC AND INFLAMMATORY DISEASES | PURDUE RESEARCH FOUNDATION | 2022-12-29 | — | — | US | disclosed |
| CN-114901315-A | Fibroblast Activation Protein (FAP) -targeted imaging and treatment of cancer and other fibrotic and inflammatory diseases | 普渡研究基金会 | 2022-08-12 | — | — | CN | disclosed |
| EP-4031184-A1 | FIBROBLAST ACTIVATION PROTEIN (FAP)-TARGETED IMAGING AND THERAPY OF CANCERS AND OTHER FIBROTIC AND INFLAMMATORY DISEASES | Purdue Research Foundation (US) | 2022-07-27 | — | — | EP | disclosed |
| US-20210096081-A1 | POLYMER DYE FOR DETECTING HYDROGEN PEROXIDE AND STRUCTURE FOR DETECTING HYDROGEN PEROXIDE | CANON KABUSHIKI KAISHA (JP) | 2021-04-01 | — | — | US | disclosed |
| WO-2021055641-A1 | FIBROBLAST ACTIVATION PROTEIN (FAP)-TARGETED IMAGING AND THERAPY OF CANCERS AND OTHER FIBROTIC AND INFLAMMATORY DISEASES | PURDUE RESEARCH FOUNDATION (US) | 2021-03-25 | — | — | WO | disclosed |
| US-20120308646-A1 | TETRACYCLIC ANTHRAQUINONES POSSESSING ANTI-CANCER PROPERTIES | ZHANG HESHENG (CN) | 2012-12-06 | — | — | US | disclosed |
| US-20090325894-A1 | TETRACYCLIC ANTHRAQUINONES POSSESSING ANTI-CANCER PROPERTIES | ZHANG HESHENG | 2009-12-31 | — | — | US | disclosed |
| EP-2123283-A1 | THE TETRACYCLIC ANTHRAQUINONES POSSESSING ANTI-CANCER EFFECT | Tianjin Hemey Bio-Tech Co., Ltd. (CN) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213735-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | MEN1 601/4885GAA 3092/4885KMT2A 3160/4885 |
| US-20090325894-A1 | TETRACYCLIC ANTHRAQUINONES POSSESSING ANTI-CANCER PROPERTIES | GLS2, GLS, VIP | MEN1 838/4885GAA 1032/4885KMT2A 3262/4885 |
| US-20120308646-A1 | TETRACYCLIC ANTHRAQUINONES POSSESSING ANTI-CANCER PROPERTIES | ALAD, SLC27A2, ANTXR2 | MEN1 2676/4885GAA 703/4885KMT2A 3885/4885 |
| US-20220409747-A1 | FIBROBLAST ACTIVATION PROTEIN (FAP)-TARGETED IMAGING AND THERAPY OF CANCERS AND OTHER FIBROTIC AND INFLAMMATORY DISEASES | FAP, FIBP, FGFR1 | MEN1 1279/4885GAA 282/4885KMT2A 3758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.